US · ATHA
Athira Pharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bothell, WA 98011
- Website
- athira.com
Price · as of 2024-12-31
—
Market cap 16.53M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $215.60 | ||||
| 2021 | $96.60 | ||||
| 2022 | $26.60 | ||||
| 2023 | $35.80 | ||||
| 2024 | $3.41 |
AI valuation
Our deep-learning model estimates Athira Pharma, Inc.'s (ATHA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATHA | Athira Pharma, Inc. | $4.19 | 16.53M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| ADTX | Aditxt, Inc. | $5.70 | 122.64K | +10,291,728% | +62,197,962% | — | +350,461,223% | 0.00 | 0.02 | 1.28 | 30.55 | -0.01 | 0.02 | -367.95% | -20796.36% | -25708.85% | -276.39% | 7.12% | -89.79% | 0.78 | -3.78 | 0.09 | 35.64 | -0.23 | 3863.00% | -7923.00% | -984.00% | -9785.19% | -0.72 | 4.28% | 0.00% | 0.00% | 8689.62% | 29.64 | 49.27 | -6164.42 | -10.97 |
| APLM | Apollomics, Inc. | $12.16 | 13.42M | +1,291% | +1,889% | — | +30,675% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| CRIS | Curis, Inc. | $1.42 | 17.75M | +255% | -18% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CTXR | Citius Pharmaceuticals, I… | $1.37 | 15.31M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| DARE | Daré Bioscience, Inc. | $1.84 | 16.28M | +11,527% | -36% | — | +2,159% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| FBLG | FibroBiologics, Inc. Comm… | $0.37 | 15.52M | — | — | — | — | -1.01 | 3.05 | — | -0.92 | -4.28 | 3.05 | 0.00% | — | — | -419.44% | -1119.26% | -143.08% | 0.39 | -81.61 | 3.61 | 2.78 | 0.14 | 2353.00% | — | 3782.00% | -88.80% | -9.32 | -1119.73% | 0.00% | 0.00% | 0.00% | -0.98 | -0.98 | — | -9.77 |
| ICU | SeaStar Medical Holding C… | $0.51 | 14.12M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| LNAI | Lunai Bioworks Inc. | $1.17 | 20.82M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| LPTX | Leap Therapeutics, Inc. | $0.41 | 16.98M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| MBRX | Moleculin Biotech, Inc. | $0.48 | 14.41M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
- CEO
- Mark J. Litton
- Employees
- 26
- Beta
- 2.97
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).